Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens-Reference-Cited by-同舟云学术

Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens

Published:2014-04-30 Issue:6 Volume:89 Page:616-620
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Biran Noa¹,Malhotra Jyoti¹,Bagiella Emilia²,Cho Hearn Jay¹,Jagannath Sundar¹,Chari Ajai¹

Affiliation:

1. Division of Hematology and Medical Oncology; Department of Medicine and the Tisch Cancer Institute; Icahn School of Medicine at Mount Sinai; New York New York

2. Department of Health Evidence and Policy; Center for Biostatistics, Icahn School of Medicine at Mount Sinai; New York New York

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23705/fullpdf

Reference22 articles.

1. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie;Kapoor;Mayo Clin Proc,2010

2. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation;Hanamura;Blood,2006

3. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols;Waheed;Cancer,2011

4. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p;Neben;Blood,2012

5. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma;Richardson;Blood,2010

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study;Hematological Oncology;2024-02-25

2. Efficacy Analysis of Bortezomib Combined with Lenalidomide in Newly Diagnosed Multiple Myeloma with 1q21 Gain/Amp;Technology in Cancer Research & Treatment;2024-01

3. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities;Leukemia & Lymphoma;2023-06-10

4. The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse;Cancer;2023-01-27

5. Multiple myeloma with isolated central nervous system relapse after autologous stem cell transplantation: A case report and review of the literature;Frontiers in Oncology;2022-11-25